Interleukin-4: A multifunctional cytokine

Inmunologia

Volumn 22, Issue 2, 2003, Pages 215-224

  Zamorano, Jose ^a   Rivas, M D ^a   Perez G M ^a  

^a HOSPITAL SAN PEDRO DE ALCÁNTARA   (Spain)

Author keywords

Asthma; Interleukin 4; JAK kinases; Rheumatoid arthritis; STAT6

Indexed keywords

CELL SURFACE RECEPTOR; INTERLEUKIN 13 RECEPTOR; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; INTERLEUKIN 4ALPHA RECEPTOR; JAK TYROSINE KINASE; PROTEIN TYROSINE KINASE; STAT6 PROTEIN; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG;

APOPTOSIS; ASTHMA; AUTOIMMUNE DISEASE; CANCER; CELL DIFFERENTIATION; CELL PROLIFERATION; CELL SURFACE; CELL TYPE; DRUG TARGETING; HEMATOPOIETIC CELL; HUMAN; IMMUNOPATHOLOGY; IMMUNOREGULATION; NONHUMAN; PROTEIN FUNCTION; REVIEW; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; TH2 CELL;

EID: 0038035229     PISSN: 02139626     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (95)

1. Paul WE. Interleukin-4: a prototypic immunoregulatory lymphokine. Blood 1991; 77: 1859-1870.
2. Nelms K, Keegan AD, Zamorano J, Ryan JJ, Paul WE. The IL-4 receptor: signaling mechanisms and biologic functions. Annu Rev Immunol 1999; 17: 701-738.
3. Vitetta ES, Ohara J, Myers C, Layton, J, Krammer PH, Paul WE. Serological, biochemical, and functional identity of B-cell stimulatory factor-1 and B cell differentiation factor for IgG1. J Exp Med 1985; 162: 1726-1731.
4. Zubiaga AM, Muñoz E, Huber BT. IL-4 and IL-2 selectively rescue Th cell subsets from glucocorticoid-induced apoptosis. J Immunol 1992; 149: 107-112.
5. Illera, VA Perandones CE, Stunz LL, Mower DA, Ashman RF. Apoptosis in splenic B lymphocytes. Regulation by protein kinase C and IL-4. J Immunol 1993; 151: 2965-2973.
6. Seder RA, Paul WE, Davis MM, De St Groth BF. The presente of interleukin-4 during in vitro priming determines the lymphokine-producing potential of CD4+ T cells from T ceU receptor transgenic mice. J Exp Med 1992; 179: 1091-1098.
7. Mosmann TR, Coffman RL. Th1 and Th2 cells: Different pattern of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989; 7: 145-173.
8. Zamorano J, Kelly AE, Austrian J, Wang HY, and Keegan AD. Costimulation of resting B lymphocytes alters the IL-4-activated IRS2 signaling pathway in a STAT6 independent manner: implications for cell survival and proliferation. Cell Res. 2001. 11: 44-54.
9. Zamorano J, Wang HY, Wang LM, Pierce JH, Keegan AD. IL-4 protects cells from apoptosis via the insulin receptor substrate pathway and a second independent signaling pathway. J Immunol 1996; 157: 4926-4934.
10. Yanagida M, Fukamachi H, Ohgami K, Kuwaki T, Ishii H, Uzumaki H, et al. Effects of T-helper 2-type cytokines, interleukin-3 (IL-3), IL-4, IL-5, and IL-6 on the survival of cultured human mast cells. Blood 1995; 86: 3705-3714.
11. Lutz MB, Schnare M, Menges M, Rossner S, Rollinghoff M, Schuler G, et al. Differential functions of IL-4 receptor types I and II for dendritic cell maturation and IL-12 production and their dependency on GM-CSF. J Immunol 2002; 169: 3574-3580.
12. Finkelman FD, Shea-Donohue T, Goldhill J, Sullivan CA, Morris SC, Madden KB, et al. Cytokine regulation of host defense against parasitic intestinal nematodes. Annu Rev Immunol 1997; 15: 505-533.
13. Urban JF Jr, Noben-Trauth N, Donaldson DD, Madden KB, Morris SC, Collins M, et al. IL-13, IL-4Ralpha, and Stat6 are required for the expulsion of the gastrointestinal nematode parasite N. brasiliensis. Immunity 1998; 8: 255-264.
14. Kay AB. Allergy and allergic diseases. N Engl J Med 2001; 344:30-37.
15. Feldmann M, Brennan FM, Maini RN. Role of cytokines in rheumatoid arthritis. Annu. Rev Immunol 1996; 14: 397-440.
16. Grunewald SM, Werthmann A, Schnarr B, Klein CE, Brocker EB, Mohrs M, et al. An antagonistic IL-4 mutant prevent type I allergy in the mouse: inhibition of the IL-4-13 receptor system completely abrogates humoral immune response to allergen and devel-opment of allergic symptoms in vivo. J Immunol 1998; 160: 4004-4009.
17. Corry DB, Folkesson HG, Warnock ML, Erle D, Matthay MA, Wiener-Kronish JP, et al. Interleukin-4, but not interleukin 5 or eosinophils, is required in a murine model of acute airway hyperreactivity. J Exp Med 1996; 183: 109-117.
18. Tomkinson A, Duez C, Cieslewicz G, Pratt JC, joetham A, Shanafelt MC et al. A murine receptor antagonist that inhibis IL-4- and IL-13-induced responses prevents antigen-induced airway eosinophilia and airway hyperresponsiveness. J Immunol 2001; 166: 5792-5800.
19. Orchansky PL, Kwan R, Lee F, Schrader JW. Characterization of the cytoplasmic domain of interleukin-13 receptor-alpha. J Biol Chem. 1999; 274: 20818-20825.
20. Woods JM, Katschke KJ, Volin MV, Ruth JH, Qin S, Wu L, et al. IL-4 Adenoviral Gene Therapy Reduces Inflammation, Proinflammatory Cytokines, Vascularization, and Bony Destruction in Rat Adjuvant-Induced Arthritis. J Immunol 2001; 166: 1214-1222.
21. Morita Y, Yang J, Gupta R, Shimizu K, Shelden ED, Endres J, et al. Dendritic cells genetically engineered to express IL-4 inhibit murine collagen-induced arthritis. J Clin Invest 2001; 107: 1275-1284.
22. Finnegan A, Grusby MJ, Kaplan CD, O'Neill SK, Eibel H, Koreny T, et al. IL-4 and IL-12 Regulate Proteoglycan-Induced Arthritis Through Stat-Dependent Mechanisms. J Immunol 2002; 169: 3345-3352.
23. Benedetti S, Pirola B, Pollo B, Magrassi L, Bruzzone MG, Rigamonti D, et al. Gene therapy of experimental brain tumors using neural progenitor cells. Nat Med 2000; 6: 447-450.
24. Terabe M, Matsui S, Noben-Trauth N, Chen H, Watson C, Donaldson DD, et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nat Immunol 2000; 1: 515-520.
25. Finkeldman FD, Urban JF. The other side of the coin: The protective role of the Th2 cytokines. J allergy Clin Immunol 2001; 107: 772-780.
26. Park LS, Friend D, Grabstein K, Urdal DL. Characterization of the high affinity cell surface receptor for murine B-cell-stimulatory factor 1. Proc Natl Acad Sci USA 1987; 84: 1669-1673.
27. Mosley B, Beckmann MP, March CJ, Idzerda RL, Gimpel SI, VandenBos T, et al. The murine interleukin-4 re-ceptor: molecular cloning and character-ization of secreted and membrane bound forms. Cell 1989; 59: 335-348.
28. Russell, SM, Keegan AD, Harada N, Nakamura Y, Noguchi M, Leland P et al. Interleukin-2 receptor_-chain: a functional component of the interleukin-4 re-ceptor. Science 1993; 262: 1880-1883.
29. Oakes SA, Candotti F, Johnston JA, Chen YQ, Ryan JJ, Taylor N, et al. Signaling via IL-2 and IL-4 in JAK3-deficient severe combined immunodeficiency lympho-cytes: JAK3-dependent and independent pathways. Immunity 1996; 5: 605-615.
30. Donaldson DD, Whitters MJ, Fitz LJ, Neben TY, Finnerty H, Henderson SL, et al. The murine IL-13 receptor alpha 2: molecular cloning, characterization, and comparison with murine IL-13 receptor alpha 1. J Immunol 1998; 161: 2317-2324
31. Ihle JN. Cytokine receptor signaling. Nature 1995; 377: 591-594.
32. Miyazaki T, Kawahara A, Fujii H, Nak-agawa Y, Minami Y, Liu Zj, et al. Functional activation of JakI and Jak3 by selective association with IL-2 re-ceptor subunits. Science 1994; 266: 1045-1047.
33. Witthahn BA, Silvennoinen O, Miura O, Lai KS, Cwik C, Liu ET, et al. Involvement of the Jak-3 Janus kinase in signalling by interleukins 2 and 4 in lym-phoid and myeloid cells. Nature 1994; 370: 153-1-57.
34. Wang HY, Zamorano J, Yoerkie JL, Paul WE, Keegan AD. The IL-4-induced tyrosine phosphorylation of the insulin receptor substrate is dependent on JAK1 expression in human fibrosarcoma cells. J Immunol 1997; 158: 1037-1040.
35. Chen XH, Patel BK, Wang LM, Frankel M, Ellmore N, Flavell RA, et al. Jak1 expression is required for medi-ating interleukin-4-induced tyrosine phosphorylation of insulin receptor substrate and Stat6 signaling molecules. J Biol Chem 1997; 272: 6556-6560.
36. Murata T, Noguchi PD, Puri RK. IL-13 induces phosphorylation and acti-vation of JAK2 Janus kinase in human colon carcinoma cell lines: similarities between IL-4 and IL-13 signaling. J Immunol 1996; 156: 2972-2978.
37. Perez-G M, Melo M, Keegan AD, Zamorano J. Aspirin and salicylates inhibit the IL-4- and IL-13-induced activation of STAT6. J Immunol 2002; 168: 1428-1434.
38. Jiang H, Foltenyi K, Kashiwada M, Donahue L, Vuong B, Hehn B et al. Fes mediated the IL-4 activation of the insulin receptor substrate-2 and cellular proliferation. J Immunol; 2001: 2627-2634.
39. Hatakeyama M, Kono T, Kobayashi N, Kawahara A, Levin SD, Perlmutter RM, et al. Interaction of the IL-2 receptor with the src-family kinase p56 lck: identification of novel intermolecular association. Science 1991; 252: 1523-1528.
40. Deutsch HH, Koettniz K, Chung K, Kalthoff FS. Distintc sequence motifs within the cytoplasmic domain of the human IL-4 receptor differentially regulate apoptosis inhibition and cell growth. J Immunol 1995; 154: 3696-3703.
41. Keegan AD, Nelms K, White M, Wang LM, Pierce JH, Paul WE. An IL-4 receptor region containing an insulin receptor motif is important for IL-4-mediated IRS-1 phosphorylation and cell growth. Cell 1994; 76: 811-820.
42. Zamorano J, Keegan AD. Regulation of apoptosis by tyrosine-containing domains of IL-4R alpha: Y497 and Y713, but not the STAT6-docking tyrosines, signal protection from apoptosis. J Immunol 1998; 161: 859-867.
43. Nelms K, Snow AL, Hu-Li J, Paul WE. FRIP, a hematopoietic cell-specific rasGAP interacting protein phosphory-lated in response to cytokine stimulation. Immunity 1998; 9: 13-24.
44. Wang HY, Zamorano J, Keegan AD. A role for the insulin-interleukin (IL)-4 receptor motif of the IL-4 receptor alpha-chain in regulating activation of the insulin receptor substrate 2 and signal transducer and activator of transcription 6 pathways. Analysis by mutagenesis. J Biol Chem 1998; 273: 9898-9905.
45. Wery S, Letourneur M, Bertoglio J, Pierre J. Interleukin-4 induces activation of mitogen-activated protein kinase and phosphorylation of shc in human keratinocytes. J Biol Chem 1996; 271: 8529-8532.
46. Ryan JJ, McReynolds LJ, Huang H, Nelms K, Paul WE. Characterization of a mobile Stat-6 motif in the human IL-4 receptor. J Immunol 1998; 161: 1811-18-21.
47. Hanson EM, Dickensheets H, Qui CK, Donnelly RP, Keegan AD. Regulation of the de-phosphorylation of STAT6: Participation of Y713 in the IL-4Ra, the tyrosine phosphatase SHP-1, and the proteasome. J Biol Chem 2003; 278: 3903-3911.
48. Takeda K, Tanaka T, Shi W, Matsumoto M, Minami M, Kashiwamura S, et al. Essential role of Stat6 in IL-4 signalling. Nature 1996; 380: 627.
49. Shimoda K, van Deursen J, Sangster MY, Sarawar SR, Carson RT, et al. Lack of IL-4-induced Th2 response and IgE class switching in mice with disrupted Stat-6 gene. Nature 1996; 380: 630-633.
50. Noben-Trauth N, Shultz LD, Brombacher F, Urban JF Jr, Gu H, Paul WE. An interleukin 4 (IL-4)-independent pathway for CD4+ T cell IL-4 production is revealed in IL-4 receptor-deficient mice. Proc Natl Acad Sci USA 1997; 94: 10838-10843.
51. Kuperman, D, Schofield B, Wills-Karp M, Grusby MJ. Signal transducer and activator of transcription factor 6 (Stat6)-deficient mice are pro-tected from antigen-induced airway hyperresponsiveness and mucus production. J Exp Med 1998; 187: 939-948.
52. Ihle JN. STATs: signal transduc-ers and activators of transcription. Cell 1996; 84: 331-334.
53. Quelle, FW, Shimoda K, Thierfelder W, Fischer C, Kim A, Ruben SM. Cloning of murine STAT6 and human Stat6, Stat proteins that are tyrosine phosphorylated in responses to IL-4 and IL-3 but are not required for mitogenesis. Mol Cel Biol 1995; 15: 3336-3343.
54. Mikita T, Campbell D, Wu PG, William-son K, Schindler U. Requirements for interleukin-4-induced gene expression and functional characterization of Stat-6. Mol Cel Biol 1996; 16: 5811-5820.
55. Tinnell SB, Jacobs-Helber SM, Sterneck E, Sawyer ST, Conrad DH. STAT6, NF-kappaB and C/EBP in CD23 expression and IgE production. Int Immunol 1998; 10: 1529-1538.
56. Barks JL, McQuillan JJ, Iademarco MF. TNF-alpha and IL-4 synergistically increase vascular cell adhesion molecule-1 expression in cultured vascular smooth muscle cells. J Immunol 1997; 159: 4532-4538.
57. Bennett BL, Cruz R, Lacson RG, Man-ning AM. Interleukin-4 suppression of tumor necrosis factor alpha-stimulated E-selectin gene transcription is mediated by STAT6 antagonism of NF-kappaB. J Biol Chem 1997; 272: 10212-10219.
58. Pesu M, Aittomaki S, Takaluoma K, Lagerstedt A, Silvennoinen O. p38 Mitogen-activated protein kinase regulates interleukin-4-induced gene expression by stimulating STAT6-mediated transcription. J Biol Chem 2002; 277: 38254-38261.
59. Hershey GK, Friedrich MF, Esswein LA, Thomas ML, Chatila TA. The association of atopy with a gain-of-function mutation in the alpha subunit of the interleukin-4 receptor. N Engl J Med 1997; 337: 1720-1725.
60. Wang HY, Shelburne CP, Zamorano J, Kelly AE, Keegan AD. Effects of an allergy-associated mutation in the huIL-4Ra (Q576R) on huIL-4-induced signal transduction. J Immunol 1999; 162: 4385-4389.
61. Nicola NA, Greenhalgh CJ. The suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol 2000; 28: 1105-1112.
62. Suzuki K, Nakajima H, Kagami S, Suto A, Ikeda K, Hirose K, et al. Proteolytic processing of Stat6 signaling in mast cells as a negative regulatory mechanism. J Exp Med 2002; 196: 27-38.
63. Sherman MA, Powell DR, Brown MA. IL-4 induces the proteolytic processing of mast cell STAT6. J Immunol 2002; 169: 3811-3818.
64. Haque SJ, Harbor PC, Williams BR. Identification of critical residues required for suppressor of cytokine signaling-specific regulation of interleukin-4 signaling. J Biol Chem 2000; 275: 26500-26506.
65. Seki Y, Hayashi K, Matsumoto A, Seki N, Tsukada J, Ransom J, et al. Expression of the suppressor of cytokine signaling-5 (SOCS5) negatively regulates IL-4-dependent STAT6 activation and Th2 differentiation. Proc Natl Acad Sci USA 2002; 99: 13003-13008.
66. Grunig G, Warnock M, Wakil AE, Venkayya R, Brombacher F, Rennick DM. Requeriment for IL-13 independently of IL-4 in experimental asthma. Science 1998; 282: 2261-2264.
67. Hogan SP, Mould A, Kikutani H, Ramsay AJ, Foster PS. Aeroallergen-induced eosinophilic inflammation, lung damage, and airways hyperreactivity in mice can occur independently of IL-4 and allergen-specific immunoglobulins. J Clin Invest 1997; 99: 1329.
68. Walter DM, McIntire JJ, Berry G, McKenzie AN, Donaldson DD, DeKruyff RH, et al. Critical role for IL-13 in the development of allergen-induced airway hyperreactivity. J Immunol 2001; 167: 4668-4675.
69. Shirakawa I, Deichmann KA, Izuhara I, Mao I, Adra CN, Hopkin JM. Atopy and asthma: genetic variants of IL-4 and IL-13 signalling. Immunol Today 2000; 21: 60-64.
70. Mitsuyasu H, Izuhara K, Mao XQ, Gao PS, Arinobu Y, Enomoto T, et al. Ile50Val variant of IL-4Ra upregulates IgE synthesis and associates with atopic asthma. Nature Genetics 1998; 19: 119-120.
71. Lozano F, Places L, Vila JM, Padilla O, Arman M, Gimferrer I, et al. Identifiaction of a novel single-nucleotide polymorphism (val554Ile) and definition of eight common alleles for human IL-4Ra exon 11. Tissue Antigens 2001; 57: 216-220.
72. Borish, LC, Nelson HS, Corren J, Bensch G, Busse JJ, Whitmore JB and the IL-4R Asthma Study Group. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 2001; 107: 963-970.
73. Strait RT, Morris SC, Smiley K, Urban JF Jr, Finkelman FD. IL-4 Exacerbates Anaphylaxis. J Immunol 2003; 170: 3835-3842.
74. Urban JF, Noben-Trauth N, Schopf L, Madden KB, Finkelman FD. IL-4 receptor expression by non-bone marrow-derived cells is required to expel gastrointestinal nematode parasites. J Immunol 2001; 167: 6078-6081.
75. Davidson A, Diamond B. Autoimmune Diseases. New Engl J Med 2001; 345: 340-350.
76. Hart PH, Hunt EK, Bonder CS, Watson CJ, Finlay-Jones JJ. Regulation of surface and soluble TNF receptor expression on human monocytes and synovial fluid macrophages by IL-4 and IL-10. J Immunol. 1996; 157: 3672-3680.
77. Miossec P, Naviliat M, D'Angeac AD, Sany J, Bancherau J. low levels of Interleukin-4 and high levels of transforming growth factor b in rheumatoid synovitis. Arthritis Rheum 1990; 1180-1187.
78. Lorenz HM, Kalden JR. Biologic agents in the treatment of inflammatory rheumatic diseases. Curr Opin Rheumatol 1999; 11: 179-184.
79. Abu-Amer Y. IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. J Clin Invest 2001; 107: 1375-1385.
80. Redlich K, Hayer S, Ricci R, David JP, Tohidast-Akrad M, Kollias G, et al. Osteoclasts are essential for TNFa-mediated joint destruction. J Clin Invest 2002; 110: 1419-1427.
81. Feldmann M, Maini RN. Anti-TNF alpha therapy of rheumatoid arthritis: what have we learned? Annu Rev Immunol 2001; 19: 163-196.
82. Buchs N, Silvestri T, Giovine FS, Chabaud M, Vannier E, Duff GW, et al. IL-4 VNTR gene polymorphism in chronic polyarthritis. The rare allele is associated with protection against destruction. Rheumatology 2000; 39: 1126-1131.
83. Yoon JW, Jun HS. Cellular and molecular pathogenic mechanisms of insulin-dependent diabetes mellitus. Ann N Y Acad Sci 2001; 928: 200-211.
84. Gallichan WS, Balasa B, Davies JD, Sarvetnick N. Pancreatic IL-4 expression results in islet-reactive Th2 cells that inhibit diabetogenic lymphocytes in the nonobese diabetic mouse. J Immunol 1999; 1631: 696-1703.
85. Radu DL, Noben-Trauth N, Hu-Li J, Paul WE, Bona CA. A targeted mutation in the IL-4Ra gene protects mice against autoimmune diabetes. Proc Natl Acad Sci USA 2000; 97: 12700-12704.
86. Ghoreschi K, Thomas P, Breit S, Dugas M, Mailhammer R, van Eden W, et al. Interleukin-4 therapy of psoriasis induces Th2 responses and improves human autoinmune disease. Nature Medicine 2003; 9: 40-46.
87. Youssef S, Stuve O, Patarroyo JC, Ruiz PJ, Radosevich JL, Hur EM, et al. The HMG-CoA reductase inhibitor, atorvastatin, promotes a Th2 bias and reverses paralysis in central nervous system autoimmune disease. Nature 2002; 420: 78-84.
88. Sarfati M, Mateo V, Baudet S, Rubio M, Fernandez C, Davi F, et al. Sildenafil and vardenafil, types 5 and 6 phosphodiesterase inhibitors, induce caspase-dependent apoptosis of B-chronic lymphocytic leukemia cells. Blood 2003; 101: 265-269.
89. Copie-Bergman C, Boulland ML, Dehoulle C, Möller P, Farcet JP, Dyer M, et al. Interleukin 4-induced gene 1 is activated in primary mediastinal large B-cell lymphoma. Blood 2003; 101: 2756-2761.
90. Whitehead RP, Lew D, Flanigan RC, Weiss GR, Roy V, Glode ML, et al. Phase II trial of recombinant human interleukin-4 in patients with advanced renal cell carcinoma: a southwest oncology group study. J Immunother 2002; 25: 352-358.
91. Lundin J, Kimby E, Bergmann L, Karakas T, Mellstedt H, Osterborg A. Interleukin 4 therapy for patients with chronic lymphocytic leukaemia: a phase I/II study. Br J Haematol 2001; 112: 155-160.
92. Taylor CW, LeBlanc M, Fisher RI, Moore DF Sr, Roach RW, Elias L, et al. Phase II evaluation of interleukin-4 in patients with non-Hodgkin's lymphoma: a Southwest Oncology Group trial. Anticancer Drugs 2000; 11: 695-700.
93. Gitlitz BJ, Figlin RA, Kiertscher SM, Moldawer N, Rosen F, Roth MD. Phase I trial of granulocyte macrophage-colony stimulating factor and interleukin-4 as a combined immunotherapy for patients with cancer. J Immunother 2003; 26: 171-178.
94. Valentin A, Lu W, Rosati M, Schneider R, Albert J, Karlsson A, et al. Dual effect of interleukin 4 on HIV-1 expression: Implications for viral phenotypic switch and disease progression. Proc Natl Acad Sci USA 1998; 95: 8886-8891.
95. Relloso M, Puig-Kroger A, Pello OM, Rodriguez-Fernandez JL, de la Rosa G, Longo N, et al. DC-SIGN (CD209) expression is IL-4 dependent and is negatively regulated by IFN, TGF-beta, and anti-inflammatory agents. J Immunol 2002; 168: 2634-2643.